These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34240493)

  • 1. Persistent activation of the mammalian target of rapamycin signalling pathway in cutaneous squamous cell carcinomas in cats.
    Sanz Ressel BL; Massone AR; Barbeito CG
    Vet Dermatol; 2021 Dec; 32(6):675-e180. PubMed ID: 34240493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of selected phosphoproteins of the mTOR signalling pathway in canine cutaneous squamous cell carcinoma.
    Sanz Ressel BL; Massone AR; Barbeito CG
    Vet J; 2019 Mar; 245():41-48. PubMed ID: 30819424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulated Expression of Phosphorylated Epidermal Growth Factor Receptor and Phosphatase and Tensin Homologue in Canine Cutaneous Papillomas and Squamous Cell Carcinomas.
    Sanz Ressel BL; Massone AR; Barbeito CG
    J Comp Pathol; 2020 Jan; 174():26-33. PubMed ID: 31955800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated expression of the key effectors of the mammalian target of rapamycin signalling pathway in cutaneous papillomas of dogs.
    Sanz Ressel BL; Massone AR; Barbeito CG
    Vet Comp Oncol; 2019 Dec; 17(4):522-527. PubMed ID: 31222908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of EGFR-PI3K-pAKT-mTOR-pS6 pathway in sinonasal squamous cell carcinomas.
    Muñoz-Cordero MG; López F; García-Inclán C; López-Hernández A; Potes-Ares S; Fernández-Vañes L; Llorente JL; Hermsen M
    Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):16-24. PubMed ID: 29573781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
    Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.
    Koletsa T; Petrakis G; Karayannopoulou G; Euvrard S; Kanitakis J
    Anticancer Res; 2018 Jun; 38(6):3319-3322. PubMed ID: 29848679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
    Mannella V; Boehm K; Celik S; Ali T; Mirza AN; El Hasnaouy M; Kaffa A; Lyu Y; Kafaei Golahmadi D; Leigh IM; Bergamaschi D; Harwood CA; Maffucci T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
    Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
    Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profile of the PI3K-AKT-mTOR pathway in head and neck squamous cell carcinoma: Data from Brazilian population.
    Marques AEM; Borges GA; Viesi do Nascimento Filho CH; Vianna LMS; Ramos DDAR; Castilho RM; Squarize CH; Guerra ENS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Apr; 133(4):453-461. PubMed ID: 35153184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR.
    Mei XL; Zhong S
    Chin Med J (Engl); 2019 Feb; 132(4):454-465. PubMed ID: 30707166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
    Wang Q; Zhang X; Song X; Zhang L
    Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions.
    Xu G; Fang J; Xu J; Shen Z; Huang C; Jiang Y
    Bioengineered; 2021 Dec; 12(2):9930-9938. PubMed ID: 34874800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma.
    Brown ME; Bear MD; Rosol TJ; Premanandan C; Kisseberth WC; London CA
    BMC Vet Res; 2015 Aug; 11():206. PubMed ID: 26272737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the hippo signalling pathway effector YAP during canine epidermal tumourigenesis.
    Sanz Ressel BL; Massone AR; Barbeito CG
    Res Vet Sci; 2020 Jun; 130():93-97. PubMed ID: 32155472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.